Topical insulin, a novel corneal epithelial regeneration agent in dry eye disease
Barbara Burgos‐Blasco(University of British Columbia), J.A. Gegúndez-Fernández(Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Pilar Pérez‐García(Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), José Ignacio Fernández‐Vigo(Hospital Clínico San Carlos), J.M. Benítez-del-Castillo(Universidad Complutense de Madrid), Virginia Puebla-García(Hospital Clínico San Carlos), David Díaz‐Valle(Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Daniela Rego‐Lorca(Instituto de Investigación Sanitaria del Hospital Clínico San Carlos)
Cited by 26
Related Papers
Conjunctivitis in COVID-19 patients: frequency and clinical presentation
|Graefe s Archive for Clinical and Experimental Ophthalmology|2020|86
Detecting SARS‐CoV‐2 RNA in conjunctival secretions: Is it a valuable diagnostic method of COVID‐19?
|Journal of Medical Virology|2020|81
Comparison of the efficacy of topical insulin with autologous serum eye drops in persistent epithelial defects of the cornea
|Acta Ophthalmologica|2021|68
Tear and aqueous humour cytokine profile in primary open‐angle glaucoma
|Acta Ophthalmologica|2020|62
Topical insulin for refractory persistent corneal epithelial defects
|European Journal of Ophthalmology|2020|59